This study is for participants that require an allogenic peripheral blood stem cell transplant. The purpose of this study is to compare 2 combinations of drugs to prevent graft-versus-host disease (GVHD), a serious complication of a stem cell transplant. These combinations are either Tacrolimus/methotrexate or Tacrolimus/mycophenolate mofetil/cyclophosphamide. Doctors want to know which combination is better or if they give the same results. The study will help doctors decide which treatment is best at preventing GVHD for future transplant patients. Participants can expect to be in this study for up to 2 years after transplant.
This study is for patients that have had a Hematopoietic Stem Cell Transplant (HSCT) and still have persistent Cytomegalovirus (CMV), adenovirus and/or Epstein-Barr Virus (EBV) infection; or have a Primary Immunodeficiency Disorder (PID) with one or more viral infections that persist. The primary purpose of the study is to evaluate whether most closely HLA-matched multivirus-specific T cell lines obtained from a bank of allogeneic virus-specific T cell lines (VSTs) have antiviral activity against three viruses: EBV, CMV and adenovirus. Participants can expect to be on this study for about 12 months.
This study will evaluate a new blood test which can detect organ rejection in patients who have had a kidney transplant. Blood samples will be obtained from subjects after consent and again up to 90 days afterward to test for transplant rejection.
Expression of APOL1 gene variants have been associated with higher likelihood of end stage renal disease in African Americans. In addition, kidney transplant recipients who have received a donated kidney from an African American expressing APOL1 variants have poorer outcomes with earlier transplanted kidney failure. This study will examine the occurance of the APOL1 gene variants in all African American donated kidneys, deceased and living, and African American recipients and recipients of African American donated kidneys, and to correlate the expression of these variants with outcome of the transplanted kidney and the kidney function of African American living donors. Samples of patients blood and urine will be acquired to measure the expression of the APOLO1 gene variants and associated kidney function, respectively.
The purpose of this study is to better understand what people think about genetic testing for kidney transplant. The study will be conducted at 3 transplant research centers. Participants will be asked to fill out a questionnaire about attitudes toward genetic testing and will also be asked questions about how easy the survey itself is to understand.
This study is for patients that have been diagnosed with multisystem Langerhans cell histiocytosis (LCH). The purpose of this study is to find out if prolonging the treatment and adding a drug called 6-mercaptopurine will be beneficial. Other goals include fining out if these changes will result in fewer patients having relapse of their LCH, and fewer patients having long term disease related problems. Participants can expect to be in this study for up to 24 months and will be followed on this study fir at least 5 years.
The purpose of the study is to generate a bio bank of specimens for research. We will tissue that would otherwise be discarded from clinical or surgical procedure and information from medical records. We will also collect discarded blood, urines and sputum. Collecting samples will help to better understanding the mechanisms of cardiovascular diseases, identify biomarkers for early diagnosis and to predict safety and efficacy of new therapies.
We will study how well the relatively new FDA approved pneumonia vaccine can protect older renal transplant recipients against pneumococcal illness. We will specifically study the group of renal transplants in whom the cause of renal failure was either diabetes mellitus II and/or hyoertension. We will compare the findings against those we find in younger renal transplant recipients, older healthy individuals and older persons with diabetes but normal kidney function. Healthy younger individuals will serve as controls for optimal vaccine response.
The House Calls (HC) program is an education study to address needs of minority end stage renal disease (ESRD) patients and their immediate support network to promote living kidney donation. It requires a HC educator to give a 60-90 minute education session in the patient's home or common location. The study is 3 years long and will comprise of 374 Black end stage renal disease patients who are on the kidney transplant waitlist or are being evaluated as waitlist candidates. Participants will be randomized to a usual care arm, a HC arm, or a HC plus a twice a week support mentor (via National Kidney Foundation) who will be in contact every two weeks. This study will recruit patients from Beth Israel Deaconess Medical Center in Boston, MA and the Medical University of South Carolina in SC.
Live donor kidney transplantation (LDKT) offers the most optimal survival and quality
of life benefit for those with late-stage chronic kidney disease. However, one-third of potential donors who volunteer to undergo evaluation on behalf of an intended recipient are blood-type or cross-match incompatibility. Kidney paired donation (KPD) was developed as a strategy to provide these incompatible donor-recipient pairs with an innovative opportunity for LDKT, yet its uptake by potential donors and their intended LDKT recipients is not optimal. In this study, we will evaluate the
effectiveness of a targeted video intervention designed to address common concerns
about KPD on the knowledge of KPD risks and benefits, KPD self-efficacy, and KPD
concerns in incompatible potential donors and their intended recipients.